Catalyst
Slingshot members are tracking this event:
Advaxis (ADXS) Announces Clinical Hold In Axalimogene Filolisbac Phase 1/2 Combination Study With AstraZeneca’s IMFINZI (Durvalumab)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ADXS |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 12, 2018
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Durvalumab, Imfinzi, Axalimogene Filolisbac, Phase 1/2
